Should patients with pre-existing anti-AAV antibodies be excluded from receiving intrathecally delivered AAV vectors?

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · Published 2025-11-20 · DOI 10.1016/j.omtm.2025.101631

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.omtm.2025.101631

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year
2025

Related articles